• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

ASCRS Live: Fortisite for corneal ulcers

Video

Brian Shafer, MD, discussed Fortisite and the ability to treat corneal ulcers at the 2023 ASCRS annual meeting in San Diego.

Brian Shafer, MD, discussed Fortisite and the ability to treat corneal ulcers at the 2023 ASCRS annual meeting in San Diego.

Video transcript

Editor’s note: Transcript lightly edited for clarity.

Brian Shafer, MD:

Hi, I'm Dr. Brian Shafer coming to you live from ASCRS 2023. I'm a cataract refractive cornea and glaucoma surgeon with the Schafer Vision Institute and I'm excited to talk to you about corneal ulcers.

We know that corneal ulcers are something that bogs down all of our clinics, It's usually that Friday at 5pm that walks through the door. And when a bad corneal ulcer comes through the door that's greater than one millimeter, central. And we know that we need to culture it and start fortified antibiotics. It's really difficult. The culturing piece is often done in our office. But when it comes time to get the fortified antibiotics, we're often sending our patients greater than an hour away, calling up this compounding pharmacy and trying to get this drug into their hands so that they can get it into their eye.

For the first time ever we have fortified antibiotics that we can stock on our shelves. Harrow Pharmaceutical now has Fortisite, which is fortified tobramycin and vancomycin. That we can stock on our shelves and dispense to our patients via a 503B pharmacy. And if that doesn't work out for you, you can do a 503A pharmacy and get it to them the very next day. We finally have the opportunity to treat these bad corneal ulcers, right in our clinics from the moment that we see them.

Related Videos
ASCRS 2024: Deborah Gess Ristvedt, DO, discusses third-generation trabecular micro-bypass
Arjan Hura, MD, highlights the clinical and surgical updates at CIME 2024
© 2024 MJH Life Sciences

All rights reserved.